-
Cell sub-journal: Zu Xiongbing's team at Central South University discovered a safe and effective
Time of Update: 2022-10-25
OnOctober192022, the Zu Xiongbing team of Central South Universitypublished an online titleCell Reports Medicine(IF=17 Research paper "Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study", To parallelize neoadjuvant immunotherapytislelizumab(gemcitabine and cisplatin),and neoadjuvant combination therapy(tislelizumab+ GC)exploring predictors of efficacy, which conducted a multicenter, real-world cohort study that demonstrated the highest rates of complete response and pathologic de-staging compared with neoadjuvant immunotherapy or chemotherapy.
-
The world's first clinical study of immunotherapy for small cell lung cancer published
Time of Update: 2022-10-20
ASTRUM-005 study is a phase III clinical study of anti-PD-1 monoclonal antibody H drug independently developed by Henlius Hans-form ® (serplulimab) combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), after Professor Cheng Ying reported the results for the first time at the 2022 ASCO Annual Meeting, which attracted widespread attention from global peers, and now has once again appeared on the international top academic stage, reflecting the high recognition of the international academic community.
-
The clinical results of Proclolamide in the treatment of AR+ breast cancer phase Ib were published in the international journal EJC
Time of Update: 2022-10-20
The study, published in the journal EJC, is Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis 。 The study was designed to evaluate the initial efficacy and safety of proclolamide monotherapy in patients with AR+ mBC and to determine the recommended dose for a phase II clinical trial.
-
Science Journal: Testosterone is an ally of macrophages in the fight against adrenal cancer
Time of Update: 2022-10-19
essaySexually dimorphic activation of innate antitumour immunity prevents adrenocortical carcinoma development Figure: Macrophages attack adrenal tumors in male mice.
essaySexually dimorphic activation of innate antitumour immunity prevents adrenocortical carcinoma development Figure: Macrophages attack adrenal tumors in male mice.
-
Nature sub-journal: Gene 'Achilles heel' found in ovarian and uterine cancers
Time of Update: 2022-10-16
Disrupting phosphate transport in cancer cells, such as with a protein they used to disable XPR1 in their experiments, could be an effective therapeutic strategy, the team added .
-
Nature sub-journal: Identify ways to limit metastatic cancer growth!
Time of Update: 2022-10-16
html Cancer stem cells (CSCs) are key drivers behind the progression of malignant cancers with self-renewal, high metastases and resistance to therapy .
html Cancer stem cells (CSCs) are key drivers behind the progression of malignant cancers with self-renewal, high metastases and resistance to therapy .
-
Refresh OS data! H drug appeared in the main journal of JAMA, PD-1 major breakthrough in the treatment of small cell lung cancer!
Time of Update: 2022-10-14
On September 27, 2022, the international multicenter research led by Professor Cheng Ying, ASTRUM-005 research, one of the world's top four medical journals, Journal of the American Medical Associati
-
Unveil the "cancer king"! Nature sub-journal: This marker is expected to provide an opportunity for "synthetic death"!
Time of Update: 2022-10-14
Since elevated levels of METTL16 protein are associated with defects in cellular DNA repair, can PARP inhibitors play a role in this type of pancreatic ductal carcinoma?
-
The Science sub-journal emphasizes the importance of temperature: a surprising link between circadian rhythm disorders and cancer
Time of Update: 2022-10-14
essayCircadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer Picture: Mice under "chronic jet lag" (CJL) conditions had a 68% increase in tumor burden compared to mice placed under 12 h light and 12 h dark (12:12 LD).
-
【Nature Sub-journal】Fudan Jiaotong University's latest joint study: Proteomic characterization
Time of Update: 2022-10-14
Recently, a research team analyzed the proteomes of 206 tumor tissues of gastric cancer patients receiving chemotherapy or anti-HER2-based therapy, trying to develop high-precision prognostic models to predict treatment response.
-
Nature Sub-Journal: EGFR/HER2 Dual Targeted PDC Combination for the Treatment of Pancreatic Cancer
Time of Update: 2022-10-14
:CN109954130,CN109957591)On September 20, the team published an article titled "An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated" in Nature Communications Mechanisms", which explains the efficacy of DTLL in combination with gemcitabine in vitro and explains its possible mechanism of action.
-
How much alcohol do you drink per day to increase your risk of cancer? JAMA sub-journal gives the answer!
Time of Update: 2022-10-13
A 2020 study published in the British Journal of Cancer analyzed the adjusted risk-adjusted ratio (HR) of cancer associated with total alcohol intake (drink/week) by ≥ Australian participants aged 226162 45 years (2006-2009) [4].
-
in the international top journal JAMA, H drug Hans-like combination chemotherapy first-line ® treatment of extensive small cell lung cancer positive results were released
Time of Update: 2022-10-13
On September 27, 2022, the international multicenter research led by Professor Cheng Ying, ASTRUM-005 research, one of the world's top four medical journals, Journal of the American Medical Associatio
-
the frontiers of tumor metastasis research in the journal Cancer Cell
Time of Update: 2022-10-13
With the diversification and precision of tumor treatment strategies, the prognosis of tumor patients has been effectively improved, but distal organ metastasis is still the most important cause of d
-
Nature sub-journal Ding Chen/Hou Yingyong/Liu Tianshu/Shen Kuntang of Fudan University found
Time of Update: 2022-10-13
Further studies showed that patients with high T cell receptor signaling responded to anti-HER2-based therapy; Activation of the extracellular matrix/PI3K-AKT pathway weakens the antitumor effect of trastuzumab.